Adaptive Biotechnologies: Mark Adams, Jyoti Palaniappan, Thomas Snyder
Adaptive Biotechnologies has appointed Mark Adams as chief technical officer, Jyoti Palaniappan as senior vice president of clinical diagnostics for the ImmunoSeq Dx program, and Thomas Snyder as vice president of research, ImmunoSeq Dx.
Adams has been involved in the strategy, design, and implementation of large-scale bioinformatics and data analytics programs for companies including SVB Leerink, Celmatix, Good Start Genetics, and Variagenics. He holds a PhD in cell biology from Baylor College of Medicine and completed his postdoc in computational biology at Boston University. He assumes the CTO role from Sean Nolan, who will fill a newly created role of distinguished engineer.
Palaniappan previously served as chief commercial officer for Bigfoot Biomedical. He also spent 11 years in Abbott's diabetes care business. Prior to Abbott he led global and US commercial organizations for Thermo Fisher Scientific, and provided strategic consulting services at McKinsey & Company. He holds an MBA/MPH from Emory University.
Snyder returns to Adaptive after five years as head of computational biology at Verily (formerly Google Life Sciences).